Nick Leschly beefs up his C-suite at 2seventy, hiring Bristol Myers alum to lead clinical push for next-gen CAR-Ts
As Nick Leschly looks to usher in multiple next-generation CAR-Ts into the clinic, he has recruited a seasoned exec to lead the push at 2seventy.
Steven Bernstein, a former head of integrated science, translational medicine at Bristol Myers Squibb who most recently served as Turnstone Biologics’ chief translational officer, is coming on board as chief medical officer.
“He brings both experience as a treating heme/oncology physician as well as extensive translational clinical expertise, including a deep knowledge of T-cell biology and immunology,” Leschly, who has traded the title of chief bluebird for chief kairos officer, said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.